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Abstract
Despite considerable advances in the treatment of multiple sclerosis, current drugs are only partially effective. Most patients
show reduced disease activity with therapy, but still experience relapses, increasing disability, and new brain lesions. Since there
are no reliable clinical or biological markers of disease progression, long-term prognosis is difficult to predict for individual
patients.Weidentified18studiesthatsuggestedgenesexpressedinbloodaspredictivebiomarkers.Wevalidatedtheprognostic
value of those genes with three different microarray data sets comprising 148 patients in total. Using these data, we tested
whether the genes were significantly differentially expressed between patients with good and poor courses of the disease. Poor
progression was defined by relapses and/or increase of disability during a two-year follow-up, independent of the administered
therapy. Of110 genes that havebeen proposed as predictivebiomarkers, most could not be confirmed in our analysis. However,
the G protein-coupled membrane receptor GPR3 was expressed at significantly lower levels in patients with poor disease
progression in all data sets. GPR3 has therefore a high potential to be a biomarker for predicting future disease activity. In
addition, weexamined the IL17 cytokinesand receptors in more detail and propose IL17RC asa new, promising, transcript-based
biomarker candidate. Further studies are needed to better understand the roles of these receptors in multiple sclerosis and its
treatment and to clarify the utility of GPR3 and IL17RC expression levels in the blood as markers of long-term prognosis.
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Introduction
Multiple sclerosis (MS) is a chronic, progressive and disabling
immune-mediated disorder of the central nervous system. Genetic
susceptibility, environmental exposure and immune dysregulation
play key roles in the pathogenesis of this disease [1–3]. Clinical
heterogeneity, alternating periods of worsening/recovery and
incomplete understanding of the autoreactive inflammatory pro-
cesses make diagnosis and treatment of MS challenging. Currently,
different immunomodulatory medications allow for control of the
severity and progression of the disease. Beta-interferons (IFNs),
along with glatiramer acetate (GA), are first-line drugs in the
treatment of relapsing-remitting MS (RRMS), which is the most
common MS phenotype [4,5]. The course of MS in a particular
patient depends on both individual disease activity and response to
treatment, and is typically monitored by evaluating the rate and
severity of relapses, the increase of disability (using, e.g., the
expanded disability status scale, EDSS), and changes in magnetic
resonanceimaging(MRI).However,ourabilitytopredictlong-term
progression and therapy outcome is limited. In clinical and
pharmacogenomic studies, treated patients are often categorized
into ‘‘responders’’ and ‘‘non-responders’’, mostly depending on
their relapse rate, EDSS and MRI. However, the term ‘‘non-
responder’’ is somewhat misleading and does in practice not
generally implicate the discontinuation of the treatment. Others,
therefore, distinguish ‘‘stable’’ and ‘‘breakthrough disease’’, the
latter meaning that disease activity is present despite therapy [6].
Here, we prefer to discern patients as having a ‘‘good’’ or ‘‘poor’’
disease course. Accordingly, a patient with a ‘‘poor’’ course is
characterized by a severe disease progression, which may be, but is
not necessarily, causally related to a less effective response to a drug.
As of today, the individual course of MS is more or less
unpredictable, and clinical or laboratory markers that prognosti-
cate either favorable or detrimental therapy outcomes still need to
be established. In general, females and younger patients tend to
have a slower disability progression [7]. Clinical parameters that
correlate with poor prognosis include more severe initial
symptoms, incomplete recovery from the first attack, and a short
interval between the first and second attacks [8,9]. MRI measures,
such as T2 lesion volume, are useful early in the disease [10], but
later on, they have only a weak predictive strength [11,12]. In
recent years, many efforts have therefore been devoted to
identifying molecular biomarkers in blood or cerebrospinal fluid
(CSF) to better monitor disease evolution, estimate individual
disease activity, and predict clinical improvement/worsening and
therapy response [13]. The most debated biomarkers are drug-
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loss of the clinical efficacy of the medication [4]. Up to one-third of
IFN-treated patients develops antibodies against the drug,
depending on the IFN-beta product used [14]. IFN NAb positivity
can be evaluated indirectly by measuring the capacity of IFN to
induce the gene expression of MX1 [15]. Low MX1 induction, i.e.
presence of NAbs, predicts the risk of both new relapses and
increase of disability [16-18]. However, routine IFN NAb testing is
still rarely performed in clinical practice.
Several transcriptional and protein profiling studies have been
carried out in the field of MS, particularly to elucidate short- and
long-term gene regulatory effects of IFN-beta treatment [19,20].
Four gene expression microarray and seven RT-PCR studies, as
well as seven protein analyses, described blood-based biomarkers
that may allow for the long-term prognosis of MS (Tables 1 and 2)
[21–38].Inthese18studies,mRNAorproteinlevelswereevaluated
at a single time point in a group of mostly RRMS patients. Some
authors discovered further potentially predictive markers in the
blood by comparing changes in gene expression during IFN-beta
treatment between clinical responders and non-responders
[26,35,36,39–43]. Others again proposed biomarkers of short-term
clinical changes [44–46], e.g., high MMP9 and low TIMP1 serum
protein levels were observed 1 month prior to the appearance of
new gadolinium-enhancing lesions [46]. Several findings suggest
that individual differences in endogenous type I IFN activity
correlate with different long-term therapeutic outcomes to IFN-beta
administration [25,26,37,47,48]. An interesting study was published
by Axtell et al., who observed elevated pre-treatment serum
concentrations of both IFN-beta and IL17F in a subgroup of IFN-
beta non-responders [22], and later incorporated IL7 into this
setting [33]. Further molecular markers indicative of MS progres-
sion have been proposed, e.g., high protein levels of CXCL13 and
TNFinCSFwere associated withan unfavorableprognosis [49,50],
high vitamin D levels were shown to reduce the hazard of relapse
[51], single-nucleotide polymorphisms at the intronic regions of
GPC5 [52] and alleles at the HLA-DRB1 locus have been linked to
poor disease course [53], anti-alpha-glucose-based glycan IgM
antibodies in serum were shown to confer a higher risk for relapses
[54], and intrathecal IgM synthesis has been related to the onset of
new relapses and worse EDSS changes [55,56].
However, with a few exceptions such as NAbs to IFN, most of
the suggested potentially prognostic biomarkers or marker sets
have not been confirmed in a completely independent analysis.
The findings of the 18 studies, which searched for blood expression
markers to be measured at a single time point, are also quite
inconsistent. Overall, 110 different genes have been nominated in
these studies (Tables 1 and 2). Nine of those genes (IFNAR1,
IFNB1, IL1B, TNFSF10, TGF-beta, ITGA4, IL10, IL12A and
FAS) each were identified in two studies. Higher mRNA and
protein expression levels of TNFSF10 have been found in patients
who are progression-free for at least 6 months on IFN-beta
treatment [32,38]. Increased levels of IFNAR1 and IL1B were
observed prior to IFN-beta therapy in non-responders by
Comabella et al. [26] and recently confirmed in a subsequent
publication of the same group [25]. The lack of response to this
treatment has also been related to an elevated endogenous
expression of IFN-beta (IFNB1) on the RNA and protein level
[22,25]. TGF-beta, ITGA4, IL10, IL12A and FAS, however, have
been reported with contradicting results. For instance, TGF-beta
expression levels were described as being significantly higher in
patients with stable disease activity by Hesse et al. [32] but as
being lower in IFN-beta responders by van Boxel-Dezaire et al.
[36]. All other genes were only mentioned once. Differences in the
blood fraction analyzed, measurement technology, treatment
strategy, patient classification, data analysis and interpretation
are factors that may account for deviations in the results.
Recently, our group published two longitudinal gene expression
microarray data sets providing transcript levels in peripheral blood
mononuclear cells (PBMCs) for 25 RRMS patients receiving
subcutaneous (sc.) IFN-beta-1b [57,58] and 24 RRMS patients
receiving intramuscular (im.) IFN-beta-1a [59]. We followed these
49 patients for 5 years after therapy onset. In this work, we used
these data and publicly available data for additional 99 patients to
reassess the predictive value of the genes whose expression had
been related to disease progression in the literature (Tables 1 and
2). We complemented the list with the different members of IL17
and IL17-receptor genes because they are in the spotlight of
current autoimmune research [60–62] and increased levels of
IL17F were noted in non-responders to IFN-beta therapy [22].
Possible clinical implications and functional roles of the affirmed
gene markers will be discussed.
Methods
Study concept
So far, the expression status of 110 genes has been proposed in
the literature to be an estimate of the advancement of MS
(Tables 1 and 2). Different therapies were prescribed to the
patients in the 18 associated studies, and the patients were
typically grouped according to disease progression or therapeutic
response by clinical evidence observed within two years after
blood sampling. Most of the genes were also measured in the
gene expression data we published lately [57–59]. Therefore, we
used the number of relapses and changes in EDSS during a two-
year follow-up to classify our 49 patients into cohorts with good
and poor disease progression. We then evaluated the genes for
differential expression between the groups. The list of examined
genes was complemented by five IL17 and five IL17R genes. The
predictive value of each gene was assessed using basic univariate
statistics, even if in some of the 18 original studies very complex
predictors had been built combining two or more genes even in
non-linear relationships. For the subset of genes that are
differentially expressed between the good and the poor outcome
groups in our data, we examined whether there was further
support for their clinical relevance in the expression data of other
studies.
Clinical classification of the patients
We grouped the 49 RRMS patients using different criteria.
First, we allocated patients to the ‘‘very poor’’ group if they
showed a rapid worsening of disability as reflected by an increase
of more than one point in the EDSS within two years after
measuring the PBMC gene expression. In addition, we defined a
‘‘poor’’ group, which extended the ‘‘very poor’’ group with
patients who had at least one relapse during the two-year follow-
up. The ‘‘good’’ group of patients was free of relapses and
neurologically relatively stable. For classification of the patients, it
was not important whether they were still treated with IFN-beta
after two years. If so, disease progression depended on both
individual course of the disease and individual benefit of the
therapy. MRI scans of the brain (1.5 Tesla) were mostly performed
before IFN therapy onset as well as after a few years, and were
analyzed for the accumulation of T2 lesion burden independently
by two experienced neurologists following the recommendations
by Sailer et al. [63]. Some patients were tested for NAbs using the
MX1 induction assay, but this assay was not routine. Clinical data
accompany the gene expression data in the Gene Expression
Omnibus (GEO) database (accession GSE19285 and GSE24427).
Multiple Sclerosis Blood Biomarker Reassessment
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Publication Study Characteristics Clinical Groups Number of Genes List of Genes
Achiron et al.,
Clin Exp
Immunol,
2007 [21]
Patients: 53 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, Sample: PBMC RNA,
Platform: Affymetrix
HG-U133 A and -U95
Good: no progress in
neurological disability
and no relapse in 2-year
follow-up, Poor: progress
with and without relapses
Suggested: 29,
Affymetrix custom: 25,
Affymetrix original: 56
ADD1, C19orf29, CA11, CCL17, CD44,
CRYGD, DNM1, DR1, GNMT, GPR3,
GSTA1, HAB1, HSPA8, IGLJ3, IL3RA,
KLF4, KLK1, MUC4, NINL, ODZ2, PTN,
RRN3, S100B, TOP3B, VEGFB, (COL11A2,
IGLV2-23, TPSB2, TRB@)
Axtell et al.,
Nat Med,
2010 [22]
Patients: 26 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, Sample:
serum proteins, Platform:
Multiplex Bead Analysis
Good and Poor: not
exactly declared; based
on the number of relapses
and steroid interventions
within 2-year follow-up
Suggested: 2,
Affymetrix custom: 2,
Affymetrix original: 1
IL17F, IFNB1
Baranzini et al.,
PLoS Biol,
2005 [23]
Patients: 52 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, Sample:
PBMC RNA, Platform:
real-time RT-PCR
Good: no relapse and no
EDSS increase after 2-year
follow-up, Poor: two or
more relapses and EDSS
increase of at least one point
Suggested: 12,
Affymetrix custom: 11,
Affymetrix original: 29
CASP2, CASP3, CASP7, CASP10,
CFLAR, IL12RB1, IL4R, IRF2, IRF4,
MAP3K1, STAT4, (IRF6)
Bartosik-Psujek
and Stelmasiak,
Clin Neurol
Neurosurg,
2006 [24]
Patients: 29 RRMS,
Treatment: IFN-a ˆ-1a im,
IFN-a ˆ-1b sc, Sample: serum
proteins, Platform: ELISA
Good: fewer relapses during
the 2 years on therapy than
during the 2 years before
therapy or an improved EDSS,
Poor: Unchanged or higher
relapse rate and EDSS
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 1
IL10
Bustamante
et al., Ann
Neurol,
2011 [25]
Patients: 85 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, Sample:
monocyte surface proteins,
PBMC RNA, Platform:
real-time RT-PCR, FACS
Good: no relapse and no
EDSS increase after 2-year
follow-up, Poor: one or
more relapses and EDSS
increase of at least one point
Suggested: 4,
Affymetrix custom: 4,
Affymetrix original: 6
IFNAR1, IFNB1, IL1B, IRAK3
Comabella
et al., Brain,
2009 [26]
Patients: 47 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, Sample:
PBMC RNA, monocyte
surface proteins, Platform:
Affymetrix HG-U133
Plus 2.0, FACS
Good: no relapse and no
EDSS increase after 2-year
follow-up, Poor: one or
more relapses and EDSS
increase of at least one point
Suggested: 28,
Affymetrix custom: 26,
Affymetrix original: 34
ATF3, CCR1, CXCL10, CXCL2, EGR3,
HERC5, IER3, IFI44, IFIT1, IFIT2, IFIT3,
IFNAR1, IL1B, IL1RN, ISG15, MARCKS,
NAMPT, NFKBIZ, OAS3, OASL, PNPT1,
PPP1R15A, PTX3, RSAD2, STAT1, TNF,
(APOL6, RASGEF1B)
Drulovic et al.,
J Neuroimmunol,
2009 [27]
Patients: 35 RRMS,
Treatment: IFN-a ˆ-1b sc,
Sample: PBMC RNA,
Platform: real-time
RT-PCR
Good: relapse rate
reductionof .30% compared
with pre-treatment and
EDSS increase of less than
one point after1-year
therapy, Poor: EDSS
increase and relapses
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 1
TBX21
Eikelenboom
et al., J
Neuroimmunol,
2005 [28]
Patients: 21 RRMS,
Treatment: none,
Sample: T-cell surface
proteins, Platform: FACS
no grouping, patients
were evaluated by T1
lesion load changes in
MRI scans performed
before study onset and
after several years
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 3
ITGA4
Gilli et al.,
Arch Neurol,
2011 [29]
Patients: 101 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, GA,
Sample: whole blood RNA,
Platform: real-time RT-PCR
Good: administration of
first-line therapy for more
than 2 years of follow-up or
discontinuation due to
pregnancy, Poor: switch
to second-line treatments
Suggested: 3,
Affymetrix custom: 3,
Affymetrix original: 7
NR4A2, SOCS2, TNFAIP3
Eighteen studies nominated 110 mRNA or proteins that, when measured in the blood at a single time point, may allow the prediction of an individual’s course of the
disease. The table provides study details, e.g., number of patients and technology used to quantify gene expression, as well as information on how long-term disease
progression was evaluated. In the column ‘‘Number of Genes’’, the entry ‘‘Suggested’’ gives for each study the number of genes that were proposed as predictive
markers. ‘‘Affymetrix custom’’ gives the number of custom probe sets that detect the suggested genes. Custom probe sets uniquely relate to GeneCard genes and are
defined by a custom CDF, which we used to preprocess our Affymetrix HG-U133 A and B microarray data. Genes for which no specific custom probe set exists are given
in brackets in the rightmost column. ‘‘Affymetrix original’’ gives the number of probe sets according to the original CDF, which was used by Gurevich et al. to preprocess
their Affymetrix HG-U133 A and A 2.0 data. Some genes are assayed by more than one probe set in the original annotation. Genes described as being predictive
concordantly by more than one study are written in bold in column ‘‘List of Genes’’. In addition to reassessing the prognostic value of the listed genes, we included the
cytokines IL17A-E and the receptors IL17RA-E in the analysis. In total, we examined the expression signals of 112 different genes that are represented by 112 custom
probe sets in our data and 204 original probe sets in the data by Gurevich et al., which we used for further validation of the results.
doi:10.1371/journal.pone.0029648.t001
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Experimental details of the time-course gene expression analysis
of PBMCs from 49 patients can be found in the original articles
[57–59]. The preprocessing of the data is described in Hecker et
al. [59]. Briefly, blood samples were obtained for all patients
immediately prior to the first IFN-beta injection and at different
time points during IFN-beta therapy. PBMC RNA was extracted,
processed, labeled and hybridized to Affymetrix HG-U133 A and
B oligonucleotide arrays. A custom chip definition file (CDF) was
used to preprocess the raw probe intensities with the MAS5.0
algorithm. The custom CDF was based on the information
contained in the GeneAnnot database, version 1.9, and the
GeneCards database, version 2.41 (http://www.xlab.unimo.it/
GA_CDF/) [64]. Compared to the original CDF from Affymetrix,
the custom CDF defines a set of probe sets, where each probe set
contains all specific probes for one particular gene. This
arrangement ensures a one-to-one correspondence between genes
and custom probe sets. Data normalization was performed
separately for chip types A and B and each of the two data sets
by a loess fit to the data with span=0.05 using the R package
‘‘affy’’. Each A- and B-chip yielded mRNA abundances of 12175
and 7771 human genes, respectively. In this reassessment study,
we only analyzed the pre-treatment (baseline) data of the
predictive gene candidates (Tables 1 and 2). The full raw and
processed microarray data have been deposited according to the
MIAMI guidelines in the GEO database (accession GSE19285
Table 2. Table 1 continued.
Publication Study Characteristics Clinical Groups Number of Genes List of Genes
Gurevich et al.,
BMC Med
Genomics,
2009 [30]
Patients: 62 MS and 32
CIS, Treatment: IFN-a ˆ-1a
im or sc, IFN-a ˆ-1b sc, GA,
none, Sample: PBMC RNA,
Platform: Affymetrix
HG-U133 A and A 2.0
time to first relapse evaluated
for a maximal period of 3.5
years. Groups: relapse within
a) ,500, b) .500 and ,1264,
c) .1264 days
Suggested: 23,
Affymetrix custom: 22,
Affymetrix original: 46
C14orf169, CA2, CLCN4,
DYNC2H1, FPR2, G3BP1,
IL24, KHDRBS2, LOC51145,
PCOLCE2, PDCD2, PPFIA1,
RHBG, SMARCA1, SPN, TAF4B,
TGFB2, TP63, TRIM22, TTC28,
TUBB2B, YEATS2,
(ENSG00000245923)
Hagman et al., J
Neuroimmunol,
2011 [31]
Patients: 66 MS, Treatment:
IFN-a ˆ-1a im or sc, IFN-a ˆ-1b sc,
GA, none, Sample: serum
proteins, Platform:
LINCOplex kit
Good: unchanged EDSS
score after 1-year follow-up,
Poor: EDSS increase of
more than 0.5 points
Suggested: 2,
Affymetrix custom: 2,
Affymetrix original: 5
FAS, MIF
Hesse et al.,
Neurology,
2010 [32]
Patients: 23 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, Sample: PBMC RNA,
Platform: Affymetrix
HG-Focus
Good: no relapse and no
EDSS increase of at least
one point and no MRI
disease activity during
6-month follow-up, Poor:
relapse or worsening in MRI
Suggested: 3,
Affymetrix custom: 3,
Affymetrix original: 6
IL10, TGFB1, TNFSF10
Lee et al.,
Sci Transl
Med,
2011 [33]
Patients: 26 RRMS,
Treatment: IFN-a ˆ-1a
im or sc, IFN-a ˆ-1b sc,
Sample: serum proteins,
Platform: Multiplex
Bead Analysis
Good and Poor: not
exactly declared; based
on the number of relapses
and steroid interventions
within 2-year follow-up
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 1
IL7
Lopatinskaya
et al., Mult
Scler, 2006 [34]
Patients: 15 RRMS,
Treatment: cM-T412,
IFN-a ˆ-1a im or sc, IFN-a ˆ-1b sc,
GA, Sample: PBMC RNA,
Platform: real-time RT-PCR
no grouping, patients
were evaluated by the
increase of EDSS over a
follow-up period of
10 years
Suggested: 2,
Affymetrix custom: 2,
Affymetrix original: 5
FAS, IL12A
Soilu-Ha ¨nninen
et al., J
Neuroimmunol,
2005 [35]
Patients: 24 RRMS,
Treatment: IFN-a ˆ-1a sc,
Sample: T-cell surface
proteins, Platform: FACS
Good: unchanged or
modestly increased EDSS
during 4-year follow-up,
Poor: EDSS increase of
more than 1.0 points
Suggested: 2, Affymetrix
custom: 2, Affymetrix
original: 6
ITGA4, ITGB1
van Boxel-Dezaire
et al., Ann Neurol,
2000 [36]
Patients: 26 RRMS,
Treatment: IFN-a ˆ-1b sc,
Sample: white blood
cell RNA, Platform: RT-PCR
Good and Poor: not
exactly declared; based
on relapses, EDSS progression
and steroid interventions
within 2-year follow-up
Suggested: 3,
Affymetrix custom: 3,
Affymetrix original: 4
IL12A, IL18, TGFB1
van der Voort
et al.,
Neurology,
2010 [37]
Patients: 116 RRMS,
Treatment: IFN-a ˆ-1a im
or sc, IFN-a ˆ-1b sc, GA, none,
Sample: whole blood RNA,
Platform: real-time RT-PCR
no grouping, patients
were evaluated by time
to a first new relapse
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 1
MX1
Wandinger
et al., Lancet,
2003 [38]
Patients: 11 RRMS,
Treatment: IFN-a ˆ-1a sc,
Sample: serum proteins,
Platform: ELISA
Good: no relapse and no
EDSS or MRI worsening after
1-year follow-up, Poor: one or
more relapses and MRI
disease activity
Suggested: 1,
Affymetrix custom: 1,
Affymetrix original: 3
TNFSF10
doi:10.1371/journal.pone.0029648.t002
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Rostock’s ethics committee and carried out according to the
Declaration of Helsinki. Written informed consent was obtained
from all patients before the blood sampling.
Statistical analysis
For each gene, we compared the expression levels of the ‘‘poor’’
and the ‘‘very poor’’ group with the expression levels of the
‘‘good’’ group. The two-sample two-tailed t-test assuming unequal
variances (t-test) was used for this purpose. As an alternative, the
nonparametric two-tailed Wilcoxon rank-sum test (U test) was
applied in addition if explicitly mentioned in the text. To check
whether the patient groups were similar in demographic and
clinical parameters, we used the t-test to examine differences in
age, disease duration (months since diagnosis of definite MS) and
EDSS at baseline, as well as the number of relapses in the year
prior to the blood sampling. The female to male ratio was
compared between the groups by Fisher’s exact test. Differences in
expression and patient characteristics with p-values below 0.05
were considered statistically significant. Correlation of gene levels
and clinical parameters was assessed by Pearson’s product-
moment coefficient.
The prognostic significance of two genes, GPR3 and IL17RC,
was evaluated in more detail. First, we distinguished low and high
mRNA levels of these genes. For this purpose, receiver operating
characteristics (ROCs) were used to compare ‘‘very poor’’ and
‘‘good’’ patients and to calculate appropriate cut-off values for
defining low and high expression for both genes. Next, we
investigated whether the genes’ expression predicted the time until
a new relapse. Using the R package ‘‘survival’’, Kaplan-Meier
survival curves were constructed to visualize the proportion of
patients with no relapse after the blood sampling over time.
Patients were grouped in this analysis according to the low and
high expression of GPR3 and IL17RC, and right censoring
occurred if patients withdrew from the study during the 5-year
follow-up period. We tested whether the difference between the
survival curves was significant by calculating the logrank test.
Hazard ratios and 95% confidence intervals (CIs) were retrieved
from a Cox proportional hazards model. Further, the number of
patients with an increase in T2 lesion load in the ‘‘low’’ and
‘‘high’’ expression cohorts was compared using Fisher’s exact test.
For the subset of patients who were followed for more than 60
months in our clinic independent of the treatment, we visualized
their long-term clinical course expressed in the number of relapses
and the change in EDSS. We computed t-test p-values to evaluate
differences in these measures between patients with low or high
baseline expression of GPR3 or IL17RC. Additionally, to disclose
the main and interaction effects of the patient groups and time, a
linear model was fitted.
Further validation
For those genes that were differentially expressed in our data
between the ‘‘good’’ and ‘‘poor’’ or ‘‘good’’ and ‘‘very poor’’
groups, we searched for additional support of their predictive
capacity. This was undertaken using publicly available data from
two high-density oligonucleotide microarray studies [30,65]. The
larger data set is provided by Gurevich and coworkers [30]. They
measured the PBMC gene expression in 32 clinically isolated
syndrome (CIS) and 62 MS patients with Affymetrix HG-U133 A
and A 2.0 arrays, and reported the time until the next relapse for
each patient. Compared to our transcriptome data, they processed
the raw data using the RMA algorithm and the original CDF from
Affymetrix (a GeneAnnot-based custom CDF is not available for A
2.0 arrays). We downloaded the preprocessed data from GEO.
The data contain information about 22215 probe sets representing
roughly 13000 genes. Because the RMA method includes a log2
transformation, we calculated the antilog before conducting
statistical tests on the data. CIS and MS samples were analyzed
together if not otherwise declared. To compare the gene
expression between patients with and without a relapse during
two-year follow-up (‘‘good’’ and ‘‘poor’’ group), we used the t-test
and the U test. A gene was considered confirmed as predictive if
the t-test p-value for the corresponding probe set was lower than
0.05 and if the mean difference of ‘‘good’’ and ‘‘poor’’ had the
same sign in our data. Correlation, ROC and survival analyses
were performed as described above.
For further verification, we took into account the microarray
data published by Singh et al. [65]. The preprocessed pre-
treatment data of this study were downloaded from GEO. Since a
different gene expression platform was used (CodeLink UniSet
Human I Bioarray), not all genes measured with Affymetrix can be
found in this data set. Additionally, only five RRMS patients were
studied: one long-term IFN-beta non-responder and four respond-
ers. Therefore, a gene that was expressed significantly higher/
lower in the groups ‘‘poor’’ or ‘‘very poor’’ in our data was
considered confirmed if the single non-responder patient showed a
higher/lower expression than the other four patients. MRI
measures and NAb status of IFN-treated patients were not
specified in the studies by Singh et al. and Gurevich et al.
Blood expression levels in other diseases
For the biomarker candidates that were differentially expressed
in our data, we compared the PBMC transcript levels of our 49
MS patients with those of patients with a different neurological
disease (chronic fatigue syndrome, CFS), patients with a different
inflammatory disease (rheumatoid arthritis, RA) and healthy
subjects (HS). For this purpose, we used another microarray data
set generated in our group that comprises 19 pre-treatment RA
samples [66], and an external public data set that comprises 8 CFS
and 7 HS samples [67]. Each data set consists of Affymetrix HG-
U133 A chips and was preprocessed as described above for the MS
data set.
Results
Patient characteristics
A total of 49 MS patients were included. Two years after the
initiation of IFN-beta therapy, 5 patients had stopped the
treatment. One patient withdrew during this time period, resulting
in the complete clinical documentation for 48 patients over two
years. After 5 years, 32 patients were still under IFN-beta therapy,
and 5 patients had left the study. Clinical presentation was highly
variable; after the first two years, our patients had between 0 and 4
relapses (median=0) and an EDSS-defined change in disability of
between 21.0 and +4.5 (median=0). During the two-year follow-
up, 30 patients were relapse-free and had only a moderate increase
in the EDSS (group ‘‘good’’), and 18 patients had at least one
relapse and/or a relatively strong worsening of MS symptoms
(group ‘‘poor’’). In the latter group, 8 patients were treated with
IFN-beta-1a im., and 10 patients were treated with IFN-beta-1b
sc. Four patients showed a ‘‘very poor’’ disease progression (1 with
IFN-beta-1a im., 3 with IFN-beta-1b sc.). They had an EDSS
increase of more than one point and an average of two relapses
within the first two years. One of the ‘‘very poor’’ patients was
tested for NAbs. Because of NAb positivity, he was further treated
with steroids and mitoxantron. The baseline clinical characteristics
were similar between the ‘‘poor’’ and ‘‘good’’ groups as well as the
‘‘very poor’’ and ‘‘good’’ groups (Table 3).
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Of the 110 predictive gene candidates from the 18 studies
(Tables 1 and 2) and the 10 additional IL17-related genes, 112
genes were measured by the Affymetrix microarray set using the
GeneAnnot-based custom CDF. Hence, 8 genes could not be
analyzed with our data. The expression of 104 genes was
determined with the A-chip. For the remaining 8 genes we used
the signal intensities from the B-chip.
Significantly differential expression was found for five genes
between the ‘‘poor’’ and ‘‘good’’ groups, and 12 genes were
differentially expressed between the ‘‘very poor’’ and ‘‘good’’
groups (Table 4). GPR3 and IL1RN were identified in both
comparisons. A high statistical significance (p-value,0.001) was
only achieved by three genes (GPR3, IL17RC and TUBB2B), and
no gene was capable of a 100% accurate separation of the clinical
groups. Interestingly, IL17RA and IL17RC appeared as new
prognostic marker candidates in this analysis.
The PBMC expression levels of the shortlisted genes were then
compared between MS, other diseases (CFS and RA) and healthy
individuals. We found evidence for higher levels of IL1RN, FPR2
and IL17RC, and lower levels of IL7 in MS and RA samples
compared to CFS and HS samples (Supporting Information S1).
The different data sets used for this analysis showed a similar
distribution of signal intensities, however, they were generated in
different labs and even small differences in the experimental
protocols may have lead to biases. Therefore, we did not perform
additional statistical tests to compare the transcript levels across
the different disorders.
Next, we included the data from Gurevich et al. to further
validate the biomarker candidates. A relapse occurred in 51 of
their patients (‘‘poor’’ group, 14 CIS and 37 MS patients), while 43
patients remained relapse-free over two years (‘‘good’’ group). The
two groups were matched in age and gender (t-test and Fisher’s
exact test p-value.0.05, respectively), and 17 of the patients
started an IFN-beta therapy during the follow-up period [30]. Of
the 15 genes that were differentially expressed in our data, we were
able to confirm 8 genes with the data from Gurevich et al.
(Table 4). Five of these genes were expressed at significantly lower
levels, and 3 genes were expressed at significantly higher levels in
the PBMCs of patients with poor disease progression.
Ten of the 15 genes were also measured in the study by Singh et
al. [65]. For 5 genes, the only non-responder in their data set had
the lowest/highest expression when the gene was expressed at a
lower/higher level in the ‘‘very poor’’ or ‘‘poor’’ cohort of our
patients. Transcript levels of 9 genes were verified as being
predictive of prognosis either by the data of Gurevich et al. or by
the data of Singh et al. (Table 4). Four of these genes (GPR3,
CA11, DNM1 and RRN3) were originally proposed to distinguish
good and poor outcomes by Achiron et al. [21], and another four
of these genes (CA2, PPFIA1, CLCN4 and YEATS2) were
suggested to be markers in the publication by Gurevich et al. [30].
For the latter four genes, we expected that we would be able to
‘‘confirm’’ their differential expression when we re-used the data
from Gurevich et al. for further validation.
Signal intensities of six of the genes correlated significantly with
clinical parameters (Figure 1); for example, GPR3 expression
correlated with the age of our patients (R=0.341, p-val-
ue=0.016), and IL17RC expression correlated negatively with
EDSS at study onset (R=20.304, p-value=0.034).
Two promising markers: GPR3 and IL17RC
Two genes emerged as the most predictive potential biomarkers.
GPR3 and IL17RC were repeatedly and significantly differentially
expressed, including when the U test was used. Their enrichment
was as follows: a) they were expressed at significantly lower levels
in our data in patients with worse clinical outcomes; b) they were
expressed at significantly lower levels in the ‘‘poor’’ group of the
Gurevich et al. study; and c) in the latter, they were also expressed
at significantly lower levels in patients with at least one relapse
during the two-year follow-up when analyzing the 32 CIS and 62
MS subjects independently (Supporting Information S1). Further-
more, in the data from Singh et al., the GPR3 mRNA signal was
lower in the non-responder than in the four responders. GPR3
and IL17RC both encode cell surface receptors and are relatively
weakly expressed in PBMCs (Figure 2, Supporting Information
S1).
Cut-off values to define low and high signal intensities for the
genes were determined using ROC analysis. For our data, a GPR3
signal of ,34 and an IL17RC signal of ,70 was considered low.
While 15 of our 49 patients had ‘‘low’’ GPR3 levels, 10 of these
patients had ‘‘low’’ IL17RC levels prior to treatment with IFN-
beta. Analogously, for the data from Gurevich et al. (that were
preprocessed differently, as explained in the methods), a GPR3
signal of ,50.5 and an IL17RC signal of ,117.5 were considered
low (Supporting Information S1). There were 73 out of 94 patients
with ‘‘low’’ GPR3 levels and 53 patients with ‘‘low’’ IL17RC
levels.
Kaplan-Meier survival analyses with censoring were then
performed on both data sets. In our data, 3 patients were censored
because they were relapse-free after therapy onset and left the
study during the 5-year follow-up period. Patients with low GPR3
levels had a significantly shorter time until the next relapse in our
data (logrank test p-value=0.0001; hazard ratio 4.3, CI: 1.9–9.6)
as well as in the data from Gurevich et al. (p-value=0.0006;
Table 3. Clinical and demographic characteristics of the patients.
Patient Groups p-values
Good (n=30) Poor (n=18) Very Poor (n=4) Poor vs Good Very Poor vs Good
Age (years) 39 (69) 36 (611) 43 (615) 0.435 0.668
Gender (female:male) 21:9 12:6 3:1 1.000 1.000
Disease duration (months) 15 (633) 4 (68) 4 (63) 0.113 0.082
Relapses 1 year prior 1.10 (60.66) 0.83 (60.62) 0.50 (60.58) 0.167 0.125
EDSS 1.52 (61.16) 1.86 (60.95) 2.25 (61.19) 0.271 0.313
Patients were grouped based on relapses and EDSS changes during a two-year follow-up period. Pre-treatment parameters were similar between these groups,
although disease duration tended to be longer for the ‘‘good’’ patient group. Mean 6 standard deviation and t-test p-values are given for age, disease duration, EDSS at
baseline and the number of relapses in the year before the gene expression measurement. The female to male ratio was compared by Fisher’s exact test.
doi:10.1371/journal.pone.0029648.t003
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curves of patients with low and high IL17RC signals. The
difference was significant in the patient cohort from Gurevich et al.
(p-value=0.0009; hazard ratio 2.35, CI: 1.4–4.0) but slightly
above the significance threshold for our patients (p-value=0.0521;
hazard ratio 2.3, CI: 1.0–5.2) (Figure 3, Supporting Information
S1). We conclude that higher PBMC transcript levels of both genes
are associated with a lower risk of MS relapses.
We have complete clinical information for at least 5 years for 44
of our 49 patients. For those patients, the mean EDSS and the
mean cumulative number of relapses from baseline to year 5 are
visualized in figure 4, with patients grouped according to low and
high expression of GPR3 and IL17RC. Linear regression revealed
a significant interaction effect between the patient groups and time
for GPR3 (EDSS p-value=0.0194, relapses p-value=0.0003) and
a tendency for such an interaction effect for IL17RC (EDSS p-
value=0.0702, relapses p-value=0.0523). For 41 patients, MRI
scans were performed before as well as 3-6 years after the start of
therapy. The formation of new T2 lesions was observed in 11 of 13
patients with low GPR3 expression and 15 of 28 patients with high
GPR3 expression (p-value=0.0836).
GPR3 and IL17RC expression is correlated in our data
(R=0.409, p-value=0.0036) as well as in the data from the
Gurevich et al. study (R=0.359, p-value=0.0004). Therefore,
using both genes may not necessarily yield an improvement in the
prediction of clinical progression, but a detailed multivariate
analysis is beyond the scope of this study.
Discussion
In the past few years, several studies have proposed gene
markers whose blood expression status could allow neurologists to
predict the long-term progression of disability and relapses in
patients with MS (Tables 1 and 2). Only nine genes were reported
twice, and five of those had conflicting results (see introduction).
Reasons for such divergent findings might be the relatively small
patient cohorts examined in some of these studies, the variability
that results from the patients’ heterogeneity and the different
treatments employed (including co-medications), and the differ-
ences in molecular biological and bioinformatic tools used.
Another issue could be that the currently identified biomarker
candidates have only a moderate discriminative power. To reassess
the proposed markers, we compared in PBMC the amounts of
mRNA, which not necessarily strongly correlate with the amounts
of active protein, between patients with good and poor disease
progression during two years of follow-up. Differential expression
was tested with the t-test and a significance level of alpha=0.05.
This p-value cut-off is quite liberal because 112 genes were
evaluated. However, this less conservative statistic lowers the
chance that we miss potential markers and, therefore, confers
higher statistical power. As a limitation, our approach could not
verify combinatorial or non-linear associations. We also did not
exclude genes with very low signal intensities from the analysis,
even if it appeared that some genes could not be detected with the
Figure 1. Correlation of gene expression and clinical parame-
ters. The transcript levels of six genes correlated significantly with
clinical or demographic data of the patients (Pearson’s correlation p-
value,0.05). For instance, GPR3 expression correlated positively with
age, and IL17RC expression correlated negatively with EDSS. Orthog-
onal linear regression lines are shown in gray. y = year.
doi:10.1371/journal.pone.0029648.g001
Figure 2. GPR3 and IL17RC mRNA expression in PBMCs of MS patients. In our microarray data, the mRNA levels of GPR3 and IL17RC were
significantly higher in patients with ‘‘good’’ (n=30) disease outcomes than in patients with ‘‘poor’’ (n=18) or ‘‘very poor’’ (n=4) outcomes after a
two-year follow-up. Patients in the ‘‘very poor’’ group are a subset of the ‘‘poor’’ group. When comparing patients with ‘‘poor’’ and ‘‘good’’ disease
progression, there is a marked overlap in the IL17RC signal intensities, but there is still a tendency toward differential expression (p=0.068). The
horizontal black lines represent the means. The figure was drawn using the function ‘‘ehplot’’ of the R package ‘‘plotrix’’.
o p,0.10,
x p,0.05,
*p ,0.005 by t-test.
doi:10.1371/journal.pone.0029648.g002
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Information S1).
Only 15 genes were differentially expressed between the ‘‘poor’’,
‘‘very poor’’ and ‘‘good’’ groups of our 49 patients (Table 4). A few
genes showed very low p-values and were also confirmed by
further validation. For the latter, we used the data from Gurevich
et al. [30] and Singh et al. [65]. To our knowledge, these are the
only publicly available oligonucleotide microarray data sets in the
field [19,20] other than ours and studies that do not (or do not yet)
provide clinical follow-up information [68–70]. Gurevich et al.
used their data to estimate the time until the next relapse by
constructing complex predictors based on the expression of up to
10 genes. CA2 is one of the genes included in those predictors. It
was verified to have lower expression levels in patients with strong
disease progression in our data and the data from Singh et al.
Interestingly, CA2 has been found lower expressed than in
controls years before the onset of MS [71].
We noticed a higher expression of IL1RN in MS patients with
‘‘good’’ clinical outcomes in our data. The average expression of
IL1RN was elevated compared to samples of healthy individuals,
but not compared to samples of RA patients (Supporting
Information S1). IL1RN inhibits the activity of the pro-
inflammatory cytokines IL1A and IL1B by binding to their
receptor. The ratio of these molecules is therefore assumed to be
critical for systemic and brain inflammation [72]. Treatment with
GA has been shown to enhance IL1RN blood levels in MS
patients, mainly by affecting monocytes. Therefore, GA triggers
less of an inflammatory response [73]. IL1RN is also up-regulated
in the blood in response to IFN-beta treatment [74]. Further,
IL1RN gene therapy improves the course of experimental
autoimmune encephalomyelitis, the animal model of MS [75].
Some patients showed an increased expression of typical IFN-
induced genes prior to the treatment with IFN-beta (data not
shown). This may indicate an elevated endogenous type I IFN-
activity in individual patients. There is currently much discussion
on whether this phenomenon is associated with better or worse
therapeutic outcomes [25,26,37,47]. TNFSF10 is an IFN-
responsive gene and was nominated as a predictive marker by
Wandinger et al. [38] and Hesse et al. [32]. High levels of the
endogenously produced IFN-beta itself and its receptor IFNAR1
have been linked to therapy non-response as well [22,25,26].
However, in our data, we could not find a differential expression of
TNFSF10, IFNB1 or IFNAR1 in patients with more severe disease
progression, and we also did not find differences in the data from
Gurevich et al. (data not shown). Moreover, none of the other
reassessed prominent IFN-induced biomarkers, such as MX1,
IFIT1, IFI44 and OASL, reached statistical significance when we
compared the expression levels of patients with good or poor long-
term clinical outcomes. Therefore, we could not confirm that the
signaling of IFN can predict the course of MS and responses to
IFN-beta administration. This may be due to the experimental
design of our study, e.g., we evaluated the RNA levels in PBMC,
while the monocyte cell surface protein level of IFNAR1 was
described to be predictive [25,26]. Sensitivity limits of the
Affymetrix microarrays may also explain why we could not
validate some of the potential blood biomarkers, e.g., IFNB1
Figure 3. Kaplan-Meier survival curves for low and high expression of GPR3 and IL17RC. Survival curves were used to visualize the
proportion of relapse-free patients from the baseline up through a 5-year follow-up. Of the 49 patients included, 34 had ‘‘high’’ and 15 had ‘‘low’’
GPR3 levels. Similarly, 39 patients had ‘‘high’’ and 10 had ‘‘low’’ IL17RC levels. Small vertical tick marks indicate losses, where a patient’s survival time
has been right-censored (n=3). More than half of the patients in the group with low GPR3 expression had a relapse within 13 months after the blood
sampling and the start of IFN-beta therapy. Low expression of the two receptors appears to correlate with a higher risk of relapses.
doi:10.1371/journal.pone.0029648.g003
Figure 4. EDSS progression and relapses for patients with low
and high expression of GPR3 and IL17RC. We have the complete
clinical data from 5 years for 44 MS patients. Patients with low baseline
expression of GPR3 (n=14) or IL17RC (n=10) tended to have a higher
rate of relapses and a stronger increase in the EDSS. Higher levels of
these receptors in PBMCs may therefore be favorable. Error bars
indicate the standard error.
o p,0.10,
x p,0.05 by t-test.
doi:10.1371/journal.pone.0029648.g004
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,15).
One of the most promising prognostic genes that emerged from
this analysis was IL17RC. IL17RC and IL17RA were both
expressed more weakly in the ‘‘very poor’’ group of our patients,
and further validation using the data by Gurevich et al. confirmed
the differential expression of IL17RC. Both membrane receptors
have not been directly associated with MS disease activity or
progression so far. They were shown to be overexpressed in whole
blood of RA patients [76], which is consistent with our results
(Supporting Information S1), and in MS, IL17RA expression in
PBMCs was described as being modulated during IFN-beta
therapy in responders [39]. IL17RC is expressed at much lower
levels than IL17RA in blood cells such as monocytes [76].
Functionally, they form a complex to mediate the effects of IL17A
and IL17F homodimers, as well as IL17A/F heterodimers [60,77].
In MS patients treated with IFN-beta, higher IL17F protein
concentrations were detected in the serum of a subset of therapy
non-responders [22]. However, we did not observe a differential
expression of IL17F at the mRNA level in our analyses. IL17A and
IL17F are mainly produced by a subset of CD4+ T cells (Th17
cells) and have been linked to a variety of inflammatory and
autoimmune conditions [62]. IL17RA and IL17RC are essential
for the signaling of these cytokines and have likely no intrinsic
activity [78]. It is tempting to speculate why patients with lower
IL17RC expression showed a more severe MS progression during
the follow-up period. The cellular composition of the blood may
be different in those patients in a way that they have lower
numbers of IL17RC producing cells. On the other hand, the
expression of this receptor in these cells may be less effective.
Interestingly, some of the many splice forms of IL17RC suggest
the existence of soluble receptors, which may act as decoy
receptors [79]. Higher levels of IL17RC may therefore be
beneficial if the cells release the receptor to dampen IL17A/F
signaling. The ratio of IL17F and soluble and membrane-bound
IL17RC may be important in MS. This opens novel therapeutic
avenues; a soluble version of IL17RC is currently being developed
as a potential drug for MS [80], while another clinical trial
(NCT01051817) is investigating the effects of a monoclonal
antibody that targets IL17A (AIN457).
The other promising gene marker is GPR3, which also encodes
a receptor. GPR3 was evaluated because it was described as being
down-regulated in RRMS patients who have a poor disease course
[21], and has therefore been patented for the prediction of MS
prognosis by Achiron and Gurevich [81]. We verified this
differential expression in our data, the data by Gurevich et al.
and the data by Singh et al. The attained p-values were ,0.01
according to both the t-test and the U test. Hence, four
independent data sets attest to GPR3 a predictive value, although
PBMC transcript levels are quite low. GPR3 is a G protein-
coupled membrane receptor predominantly expressed in the
human brain and testis. It constitutively activates G protein
G(alpha)s. As a result, adenylate cyclase is activated and therefore
cAMP production is stimulated [82]. The overexpression of GPR3
in neurons increases amyloid-beta production, which is patholog-
ically deposited in Alzheimer’s disease [83]. The sphingosine-1-
phosphate (S1P) receptors are close phylogenetic neighbors of
GPR3 [84]. S1P ligands enhance Ca2+ release from GPR3
expressing cells; therefore, GPR3 is assumed to be subject to
modulation by S1P [85]. S1Ps are hormone-like lipid signaling
molecules that are involved in many biological processes, including
platelet activation and protection of endothelial cells from
apoptosis [86]. Intriguingly, a novel class of MS drugs resembles
naturally occurring S1P; Fingolimod (FTY720), the first oral agent
for MS, acts as a S1P receptor modulator. The compound is
phosphorylated to form fingolimod-phosphate, which binds to S1P
receptors and leads to the down-regulation of lymphocyte egress
from lymph nodes into the circulation. This is assumed to reduce
systemic inflammation and lymphocyte infiltration into the CNS.
In addition, fingolimod may also have direct CNS effects because
it can cross the blood-brain barrier [87]. Similar drugs are
currently in phase II clinical trials (NCT00879658,
NCT01006265). However, to our knowledge, it is unknown
whether GPR3 is affected by these treatments – either directly or
indirectly.
More studies are needed to further clarify the ligand-dependent
functional roles of the different IL17 receptors and the different
S1P or closely related lipid receptors in the blood and brain. We
may better understand disease and treatment mechanisms if we
have more data on the cell type-specific expression of IL17RC and
GPR3. Specific experiments on DNA polymorphisms and mRNA
splice variants of these genes and on their respective protein levels
should help disclose their biological significance. This, together
with a more detailed analysis of their regulation by transcription
factors and regulatory RNAs (e.g., microRNAs as important post-
transcriptional regulators [88]) and their interactions with ligands
and other molecules, may even enhance their potential as
prognostic biomarkers for MS.
In this study, we could not ascertain to what extent the genes are
markers of a clinical response to IFN-beta therapy. While all of our
49 patients and all 5 patients in the Singh et al. study started
treatment with IFN-beta immediately after the blood sampling,
only 17 of the 94 patients in the Gurevich et al. study initiated this
therapy during follow-up. Therefore, low levels of GPR3 and
IL17RC may indicate a higher inherent disease activity, which
may be perceived as a suboptimal therapy response. This also
implies that we cannot exclude a beneficial therapeutic effect in
patients with poor outcome, at least for IFN NAb-negative
patients. The relationship of the genes’ expression and therapeutic
benefit thus remains an open question. Nevertheless, GPR3 and/
or IL17RC will be of help in individual treatment decisions, if they
can be further confirmed and established as markers of future
disease burden. This requires larger studies with long clinical
follow-up periods. Meanwhile, the need for reliable prognostic
markers is growing as more treatments with different efficacies and
risks enter the MS drug market.
In conclusion, of the 110 genes that have been proposed in the
literature as predictive markers of future clinical or MRI disease
activity, most could not be confirmed in our reassessment analysis,
which was based on PBMC RNA levels. However, GPR3 was
significantly lower expressed in patients with long-term poor
disease progression in all data sets. GPR3 is therefore the best
supported biomarker. We also investigated the IL17 cytokines and
receptors and propose IL17RC as a novel, promising transcript-
based biomarker candidate. GPR3 and IL17RC may have the
potential to facilitate improved patient care, but larger studies
employing more sensitive RNA detection methods are required to
further examine the predictive value of their blood expression
levels. In addition, we may better understand the pathophysiology
of MS if we better understand the specific roles of these receptors.
Supporting Information
Supporting Information S1 This document includes details of
the additional validation using the data from Gurevich et al. as
well as a comparison of PBMC gene expression levels in MS, two
other diseases and healthy controls.
(PDF
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